A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes
- PMID: 7563456
- DOI: 10.1001/jama.1995.03530130055028
A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes
Abstract
Objectives: To determine the risk of elevated total homocysteine (tHcy) levels for arteriosclerotic vascular disease, estimate the reduction of tHcy by folic acid, and calculate the potential reduction of coronary artery disease (CAD) mortality by increasing folic acid intake.
Data sources: MEDLINE search for meta-analysis of 27 studies relating homocysteine to arteriosclerotic vascular disease and 11 studies of folic acid effects on tHcy levels.
Study selection and data extraction: Studies dealing with CAD, cerebrovascular disease, and peripheral arterial vascular disease were selected. Three prospective and six population-based case-control studies were considered of high quality. Five cross-sectional and 13 other case-control studies were also included. Causality of tHcy's role in the pathogenesis of vascular disease was inferred because of consistency across studies by different investigators using different methods in different populations.
Data synthesis: Elevations in tHcy were considered an independent graded risk factor for arteriosclerotic vascular diseases. The odds ratio (OR) for CAD of a 5-mumol/L tHcy increment is 1.6 (95% confidence interval [CI], 1.4 to 1.7) for men and 1.8 (95% CI, 1.3 to 1.9) for women. A total of 10% of the population's CAD risk appears attributable to tHcy. The OR for cerebrovascular disease (5-mumol/L tHcy increment) is 1.5 (95% CI, 1.3 to 1.9). Peripheral arterial disease also showed a strong association. Increased folic acid intake (approximately 200 micrograms/d) reduces tHcy levels by approximately 4 mumol/L. Assuming that lower tHcy levels decrease CAD mortality, we calculated the effect of (1) increased dietary folate, (2) supplementation by tablets, and (3) grain fortification. Under different assumptions, 13,500 to 50,000 CAD deaths annually could be avoided; fortification of food had the largest impact.
Conclusions: A 5-mumol/L tHcy increment elevates CAD risk by as much as cholesterol increases of 0.5 mmol/L (20 mg/dL). Higher folic acid intake by reducing tHcy levels promises to prevent arteriosclerotic vascular disease. Clinical trials are urgently needed. Concerns about masking cobalamin deficiency by folic acid could be lessened by adding 1 mg of cobalamin to folic acid supplements.
Comment in
-
Folic acid fortification of food.JAMA. 1996 Mar 6;275(9):681; author reply 682-3. JAMA. 1996. PMID: 8594257 No abstract available.
-
Folic acid fortification of food.JAMA. 1996 Mar 6;275(9):681-2; author reply 682-3. doi: 10.1001/jama.1996.03530330025013. JAMA. 1996. PMID: 8594258 No abstract available.
-
Folic acid fortification of food.JAMA. 1996 Mar 6;275(9):682-3. JAMA. 1996. PMID: 8594259 No abstract available.
Similar articles
-
Dietary strategies for lowering homocysteine concentrations.Am J Clin Nutr. 2000 Jun;71(6):1448-54. doi: 10.1093/ajcn/71.6.1448. Am J Clin Nutr. 2000. PMID: 10837284 Clinical Trial.
-
Total homocysteine lowering treatment among coronary artery disease patients in the era of folic acid-fortified cereal grain flour.Arterioscler Thromb Vasc Biol. 2002 Mar 1;22(3):488-91. doi: 10.1161/hq0302.105369. Arterioscler Thromb Vasc Biol. 2002. PMID: 11884295 Clinical Trial.
-
Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond.JAMA. 2001 Aug 22-29;286(8):936-43. doi: 10.1001/jama.286.8.936. JAMA. 2001. PMID: 11509058
-
Homocysteine, vitamins, and coronary artery disease. Comprehensive review of the literature.Can Fam Physician. 2000 Nov;46:2236-45. Can Fam Physician. 2000. PMID: 11143583 Free PMC article. Review.
-
[Hyperhomocysteinemia: a risk factor for arterial and venous thrombosis].Vasa. 1999 Aug;28(3):151-5. doi: 10.1024/0301-1526.28.3.151. Vasa. 1999. PMID: 10483317 Review. German.
Cited by
-
Comparative Analysis of Biomarkers in Type 2 Diabetes Patients With and Without Comorbidities: Insights Into the Role of Hypertension and Cardiovascular Disease.Biomark Insights. 2024 May 4;19:11772719231222111. doi: 10.1177/11772719231222111. eCollection 2024. Biomark Insights. 2024. PMID: 38707193 Free PMC article.
-
An overview of regulation for nutraceuticals and concept of personalized nutraceuticals.J Generic Med. 2023 Jun;19(2):66-74. doi: 10.1177/17411343221150875. Epub 2023 Jan 13. J Generic Med. 2023. PMID: 38603246 Free PMC article. Review.
-
Optimal folic acid dosage in lowering homocysteine: Precision Folic Acid Trial to lower homocysteine (PFAT-Hcy).Eur J Nutr. 2024 Mar 13. doi: 10.1007/s00394-024-03344-8. Online ahead of print. Eur J Nutr. 2024. PMID: 38478042
-
Prevalence and clinical correlates of hyperhomocysteinemia in Chinese urban population with hypertension.Front Endocrinol (Lausanne). 2024 Feb 20;15:1369997. doi: 10.3389/fendo.2024.1369997. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38444590 Free PMC article.
-
Association between homocysteine and coronary artery disease-trend over time and across the regions: a systematic review and meta-analysis.Egypt Heart J. 2024 Feb 27;76(1):29. doi: 10.1186/s43044-024-00460-y. Egypt Heart J. 2024. PMID: 38409614 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous